Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Mark E. Dmytruk sold 51,169 shares of Ginkgo Bioworks stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total value of $53,727.45. Following the transaction, the insider now owns 865,079 shares in the company, valued at approximately $908,332.95. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Ginkgo Bioworks Price Performance
NYSE:DNA opened at $1.07 on Friday. The stock has a market capitalization of $2.30 billion, a PE ratio of -2.28 and a beta of 1.35. The business's 50-day simple moving average is $1.25 and its 200-day simple moving average is $1.43. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $2.55.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its earnings results on Thursday, February 29th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $34.76 million during the quarter, compared to the consensus estimate of $40.37 million. Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The company's revenue was down 64.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.04) EPS. On average, research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -0.32 earnings per share for the current year.
Wall Street Analyst Weigh In
4 coins to be the “Next Bitcoin”
From True Market Insiders | Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%...
Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
Several equities analysts have recently weighed in on DNA shares. TD Cowen cut their price objective on Ginkgo Bioworks from $7.00 to $3.00 and set an "outperform" rating on the stock in a report on Friday, March 1st. The Goldman Sachs Group cut their price objective on Ginkgo Bioworks from $1.25 to $1.10 and set a "sell" rating on the stock in a report on Monday, January 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $2.20.
Check Out Our Latest Stock Report on DNA
Institutional Investors Weigh In On Ginkgo Bioworks
Several institutional investors have recently bought and sold shares of DNA. ARK Investment Management LLC increased its position in shares of Ginkgo Bioworks by 9.0% during the 4th quarter. ARK Investment Management LLC now owns 198,606,619 shares of the company's stock worth $335,645,000 after purchasing an additional 16,414,434 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Ginkgo Bioworks by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 132,780,095 shares of the company's stock worth $224,398,000 after purchasing an additional 463,096 shares during the last quarter. BlackRock Inc. increased its position in shares of Ginkgo Bioworks by 34.6% during the 2nd quarter. BlackRock Inc. now owns 68,202,832 shares of the company's stock worth $126,857,000 after purchasing an additional 17,538,752 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Ginkgo Bioworks by 15.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 58,746,160 shares of the company's stock worth $106,331,000 after purchasing an additional 7,958,613 shares during the last quarter. Finally, State Street Corp increased its position in shares of Ginkgo Bioworks by 40.6% during the 2nd quarter. State Street Corp now owns 20,683,752 shares of the company's stock worth $38,472,000 after purchasing an additional 5,976,244 shares during the last quarter. Institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
